American Association for Cancer Research
10559965epi160958-sup-174994_2_supp_3888163_hm5c5m.pdf (31.05 MB)

Supplemental Figure 5 from Diagnostic Distinction of Malignant Melanoma and Benign Nevi by a Gene Expression Signature and Correlation to Clinical Outcomes

Download (31.05 MB)
journal contribution
posted on 2023-03-31, 14:06 authored by Jennifer S. Ko, Balwir Matharoo-Ball, Steven D. Billings, Brian J. Thomson, Jean Y. Tang, Kavita Y. Sarin, Emily Cai, Jinah Kim, Colleen Rock, Hillary Z. Kimbrell, Darl D. Flake, M. Bryan Warf, Jonathan Nelson, Thaylon Davis, Catherine Miller, Kristen Rushton, Anne-Renee Hartman, Richard J. Wenstrup, Loren E. Clarke

Supplemental Figure 5 shows a lesion from the back of a 43 year old female was classified as a superficial spreading melanoma arising within a pre-existing dysplastic nevus (Breslow thickness 1.6 mm, mitotic index 0/mm2, ulceration absent). The lesion was completely excised. The score was +4.6. Metastases to the soft tissue and skin of the upper chest were detected 56 months after diagnosis.



Background: Histopathologic examination alone can be inadequate for diagnosis of certain melanocytic neoplasms. Recently, a 23-gene expression signature was clinically validated as an ancillary diagnostic test to differentiate benign nevi from melanoma. The current study assessed the performance of this test in an independent cohort of melanocytic lesions against clinically proven outcomes.Methods: Archival tissue from primary cutaneous melanomas and melanocytic nevi was obtained from four independent institutions and tested with the gene signature. Cases were selected according to pre-defined clinical outcome measures. Malignant lesions were defined as stage I–III primary cutaneous melanomas that produced distant metastases (metastatic to sites other than proximal sentinel lymph node(s)) following diagnosis of the primary lesion. Melanomas that were metastatic at the time of diagnosis, all re-excisions, and lesions with <10% tumor volume were excluded. Benign lesions were defined as cutaneous melanocytic lesions with no adverse long-term events reported.Results: Of 239 submitted samples, 182 met inclusion criteria and produced a valid gene expression result. This included 99 primary cutaneous melanomas with proven distant metastases and 83 melanocytic nevi. Median time to melanoma metastasis was 18 months. Median follow-up time for nevi was 74.9 months. The gene expression score differentiated melanoma from nevi with a sensitivity of 93.8% and a specificity of 96.2%.Conclusions: The results of gene expression testing closely correlate with long-term clinical outcomes of patients with melanocytic neoplasms.Impact: Collectively, this provides strong evidence that the gene signature adds valuable adjunctive information to aid in the accurate diagnosis of melanoma. Cancer Epidemiol Biomarkers Prev; 26(7); 1107–13. ©2017 AACR.

Usage metrics

    Cancer Epidemiology, Biomarkers & Prevention



    Ref. manager